Novonix (ASX:NVX) won a US$100m grant from the US Department of Energy

Nick Sundich Nick Sundich, November 1, 2023

Today was a good morning for investors in Novonix (ASX:NVX). Its shares rose as much as 22% after winning a US$100m grant from the US Department of Energy.

 

Novonix (ASX:NVX) share price chart, log scale (Source: TradingView)

 

All about Novonix

Novonix has multiple ventures in the battery metals space but one of these is the PUREgraphite point venture. Puregraphite develops, manufactures and sells high performance anode materials into the global lithium-ion battery market from a factory in Chattanooga, Tennessee.

The company has been seeking funding for expansion of the project and has been negotiating with the US Department of Energy (DoE) for just over year now. The DoE finalised a US$100m award that will upgrade Chattanooga to a capacity that can handle 20,000tpa of lithium.

Production is set to begin in late 2024 and comes not long after recent export controls on Chinese graphite. The US is keen to secure its own North American battery supply chain and this grant will play a part in it.

 

All good news?

Even though Novonix shares rose today, shareholders might be disappointed that it did not rise by more and/or that shares are down nearly half in the last year.

Obviously cooling battery metal prices in the short-term have not helped its cause. And keep in mind that the company was seeking an award of up to US$150m to build the facility to handle 30,000tpa. Investors could be forgiven for resenting that the final award was lower than they had expected.

Ultimately, we think today’s news is not to be snuffed at and investors would be hard-pressed to find other ASX companies more exposed to the US battery metals supply chain than this one.

 

 

What are the Best stocks to invest in right now?

Check our buy/sell stock tips

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

iron ore prices in 2025

Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?

In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…

Zilosul

Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025

Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…

Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India

Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…